{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:52:04Z","timestamp":1791395524649,"version":"4.3.3"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100016289","name":"Dental Research Center, Tehran University of Medical Sciences","doi-asserted-by":"publisher","award":["1401\/33\/32\/279"],"award-info":[{"award-number":["1401\/33\/32\/279"]}],"id":[{"id":"10.13039\/501100016289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04566-4","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:08:10Z","timestamp":1791389290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic significance of pre-intervention circulating cytokines in digestive system cancers: a systematic review and meta-analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9764-2947","authenticated-orcid":false,"given":"Fatemeh","family":"Tajik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3407-3475","authenticated-orcid":false,"given":"Fereshteh","family":"Rezagholizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6257-6852","authenticated-orcid":false,"given":"Mahdieh","family":"Razmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4412-3435","authenticated-orcid":false,"given":"Sadegh","family":"Safaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3634-7992","authenticated-orcid":false,"given":"Mojgan","family":"Alaeddini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2548-9493","authenticated-orcid":false,"given":"Shahroo","family":"Etemad-Moghadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6656-7307","authenticated-orcid":false,"given":"Leila","family":"Eini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"issue":"3","key":"4566_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S2468-1253(23)00366-7","volume":"9","author":"S Wang","year":"2024","unstructured":"Wang S, Zheng R, Li J, Zeng H, Li L, Chen R, et al. Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: a population-based systematic analysis of GLOBOCAN. Lancet Gastroenterol Hepatol. 2024;9(3):229\u201337.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4566_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20043640","author":"SR Jardim","year":"2023","unstructured":"Jardim SR, de Souza LMP, de Souza HSP. The rise of gastrointestinal cancers as a global phenomenon: unhealthy behavior or progress? Int J Environ Res Public Health. 2023. https:\/\/doi.org\/10.3390\/ijerph20043640.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"4566_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","volume":"8","author":"Q Sun","year":"2023","unstructured":"Sun Q, Hong Z, Zhang C, Wang L, Han Z, Ma D. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Target Ther. 2023;8(1):320.","journal-title":"Signal Transduct Target Ther"},{"key":"4566_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.810539","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang J, Ma X, Ma Z, Ma Y, Wang J, Cao B. Research progress of biomarkers for immune checkpoint inhibitors on digestive system cancers. Front Immunol. 2022;13:810539.","journal-title":"Front Immunol"},{"key":"4566_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines6030087","author":"J Zhang","year":"2018","unstructured":"Zhang J, Quadri S, Wolfgang CL, Zheng L. New development of biomarkers for gastrointestinal cancers: from neoplastic cells to tumor microenvironment. Biomedicines. 2018. https:\/\/doi.org\/10.3390\/biomedicines6030087.","journal-title":"Biomedicines"},{"key":"4566_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-024-01022-w","author":"M Razmi","year":"2024","unstructured":"Razmi M, Tajik F, Hashemi F, Yazdanpanah A, Hashemi-Niasari F, Divsalar A. The prognostic importance of Ki-67 in gastrointestinal carcinomas: a meta-analysis and multi-omics approach. J Gastrointest Cancer. 2024. https:\/\/doi.org\/10.1007\/s12029-024-01022-w.","journal-title":"J Gastrointest Cancer"},{"issue":"7","key":"4566_CR7","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","volume":"187","author":"A Passaro","year":"2024","unstructured":"Passaro A, Al Bakir M, Hamilton EG, Diehn M, Andre F, Roy-Chowdhuri S, et al. Cancer biomarkers: emerging trends and clinical implications for personalized treatment. Cell. 2024;187(7):1617\u201335.","journal-title":"Cell"},{"key":"4566_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1276414","volume":"13","author":"J Huang","year":"2023","unstructured":"Huang J, Zhang Q, Pan G, Hu X, Chen D, Zhang K. Editorial: biomarkers, functional mechanisms, and therapeutic potentials in gastrointestinal cancers. Front Oncol. 2023;13:1276414.","journal-title":"Front Oncol"},{"key":"4566_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103865","volume":"180","author":"B Smolkova","year":"2022","unstructured":"Smolkova B, Kataki A, Earl J, Ruz-Caracuel I, Cihova M, Urbanova M, et al. Liquid biopsy and preclinical tools for advancing diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms. Crit Rev Oncol Hematol. 2022;180:103865.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"4566_CR10","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/annonc\/mdz196","volume":"30","author":"P Hofman","year":"2019","unstructured":"Hofman P, Heeke S, Alix-Panabieres C, Pantel K. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients? Ann Oncol. 2019;30(9):1448\u201359.","journal-title":"Ann Oncol"},{"issue":"1","key":"4566_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-02851-8","volume":"23","author":"E Gheytanchi","year":"2023","unstructured":"Gheytanchi E, Tajik F, Razmi M, Babashah S, Cho WCS, Tanha K, et al. Circulating exosomal microRNAs as potential prognostic biomarkers in gastrointestinal cancers: a systematic review and meta-analysis. Cancer Cell Int. 2023;23(1):10.","journal-title":"Cancer Cell Int"},{"key":"4566_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15225434","author":"G Alexandrou","year":"2023","unstructured":"Alexandrou G, Mantikas KT, Allsopp R, Yapeter CA, Jahin M, Melnick T, et al. The evolution of affordable technologies in liquid biopsy diagnostics: the key to clinical implementation. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15225434.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4566_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03026-7","volume":"43","author":"F Ren","year":"2024","unstructured":"Ren F, Fei Q, Qiu K, Zhang Y, Zhang H, Sun L. Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation. J Exp Clin Cancer Res. 2024;43(1):96.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"4566_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01556-2","volume":"21","author":"H Zhou","year":"2022","unstructured":"Zhou H, Zhu L, Song J, Wang G, Li P, Li W, et al. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Mol Cancer. 2022;21(1):86.","journal-title":"Mol Cancer"},{"issue":"7","key":"4566_CR15","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3390\/diagnostics10070443","volume":"10","author":"D Fernandez-Lazaro","year":"2020","unstructured":"Fernandez-Lazaro D, Hernandez JLG, Garcia AC, Castillo ACD, Hueso MV, Cruz-Hernandez JJ. Clinical perspective and translational oncology of liquid biopsy. Diagnostics (Basel). 2020;10(7):443.","journal-title":"Diagnostics (Basel)"},{"key":"4566_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1321895","volume":"14","author":"V Aran","year":"2023","unstructured":"Aran V, Lyra Miranda R, Heringer M, Carvalho da Fonseca AC, Andreiuolo F, Chimelli L, et al. Liquid biopsy evaluation of circulating tumor DNA, miRNAs, and cytokines in meningioma patients. Front Neurol. 2023;14:1321895.","journal-title":"Front Neurol"},{"key":"4566_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.692142","volume":"11","author":"AER Kartikasari","year":"2021","unstructured":"Kartikasari AER, Huertas CS, Mitchell A, Plebanski M. Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis. Front Oncol. 2021;11:692142.","journal-title":"Front Oncol"},{"issue":"15","key":"4566_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202004433","volume":"8","author":"C Liu","year":"2021","unstructured":"Liu C, Chu D, Kalantar-Zadeh K, George J, Young HA, Liu G. Cytokines: from clinical significance to quantification. Adv Sci (Weinh). 2021;8(15):e2004433.","journal-title":"Adv Sci (Weinh)"},{"issue":"5","key":"4566_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1093722","volume":"5","author":"BE Lippitz","year":"2016","unstructured":"Lippitz BE, Harris RA. Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis. Oncoimmunology. 2016;5(5):e1093722.","journal-title":"Oncoimmunology"},{"issue":"1","key":"4566_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-01711-z","volume":"29","author":"T Abdul-Rahman","year":"2024","unstructured":"Abdul-Rahman T, Ghosh S, Badar SM, Nazir A, Bamigbade GB, Aji N, et al. The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review. Eur J Med Res. 2024;29(1):124.","journal-title":"Eur J Med Res"},{"issue":"1","key":"4566_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40364-021-00327-3","volume":"9","author":"Y Qiu","year":"2021","unstructured":"Qiu Y, Chen T, Hu R, Zhu R, Li C, Ruan Y, et al. Next frontier in tumor immunotherapy: macrophage-mediated immune evasion. Biomark Res. 2021;9(1):72.","journal-title":"Biomark Res"},{"key":"4566_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.610303","volume":"11","author":"V Salemme","year":"2021","unstructured":"Salemme V, Centonze G, Cavallo F, Defilippi P, Conti L. The crosstalk between tumor cells and the immune microenvironment in breast cancer: implications for immunotherapy. Front Oncol. 2021;11:610303.","journal-title":"Front Oncol"},{"key":"4566_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061899","author":"K Wright","year":"2023","unstructured":"Wright K, Ly T, Kriet M, Czirok A, Thomas SM. Cancer-associated fibroblasts: master tumor microenvironment modifiers. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15061899.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4566_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02599-7","volume":"22","author":"B Feng","year":"2022","unstructured":"Feng B, Wu J, Shen B, Jiang F, Feng J. Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures. Cancer Cell Int. 2022;22(1):166.","journal-title":"Cancer Cell Int"},{"key":"4566_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1147883","volume":"13","author":"C Qu","year":"2023","unstructured":"Qu C, Zhang L, Cheng W, Cheng Q, Zhang J. Editorial: The interconnection between the tumor microenvironment and immunotherapy in brain tumors. Front Oncol. 2023;13:1147883.","journal-title":"Front Oncol"},{"key":"4566_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106939","volume":"88","author":"L Li","year":"2020","unstructured":"Li L, Yu R, Cai T, Chen Z, Lan M, Zou T, et al. Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment. Int Immunopharmacol. 2020;88:106939.","journal-title":"Int Immunopharmacol"},{"key":"4566_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.884592","volume":"13","author":"XC Mao","year":"2022","unstructured":"Mao XC, Yang CC, Yang YF, Yan LJ, Ding ZN, Liu H, et al. Peripheral cytokine levels as novel predictors of survival in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Immunol. 2022;13:884592.","journal-title":"Front Immunol"},{"issue":"7","key":"4566_CR28","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.21873\/anticanres.15110","volume":"41","author":"KS Rallis","year":"2021","unstructured":"Rallis KS, Corrigan AE, Dadah H, George AM, Keshwara SM, Sideris M, et al. Cytokine-based cancer immunotherapy: challenges and opportunities for IL-10. Anticancer Res. 2021;41(7):3247\u201352.","journal-title":"Anticancer Res"},{"issue":"6","key":"4566_CR29","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.rpor.2020.08.004","volume":"25","author":"P Czajka-Francuz","year":"2020","unstructured":"Czajka-Francuz P, Francuz T, Cison-Jurek S, Czajka A, Fajkis M, Szymczak B, et al. Serum cytokine profile as a potential prognostic tool in colorectal cancer patients - one center study. Rep Pract Oncol Radiother. 2020;25(6):867\u201375.","journal-title":"Rep Pract Oncol Radiother"},{"issue":"9","key":"4566_CR30","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1322242","volume":"6","author":"G Piro","year":"2017","unstructured":"Piro G, Simionato F, Carbone C, Frizziero M, Malleo G, Zanini S, et al. A circulating T(H)2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. Oncoimmunology. 2017;6(9):e1322242.","journal-title":"Oncoimmunology"},{"key":"4566_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9121916","author":"E Yang","year":"2021","unstructured":"Yang E, Chua W, Ng W, Roberts TL. Peripheral cytokine levels as a prognostic indicator in gastric cancer: a review of existing literature. Biomedicines. 2021. https:\/\/doi.org\/10.3390\/biomedicines9121916.","journal-title":"Biomedicines"},{"key":"4566_CR32","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2147\/IJWH.S347740","volume":"14","author":"C Cai","year":"2022","unstructured":"Cai C, Peng X, Zhang Y. Serum IL-6 level predicts the prognosis and diagnosis in cervical cancer patients. Int J Womens Health. 2022;14:655\u201363.","journal-title":"Int J Womens Health"},{"issue":"12","key":"4566_CR33","first-page":"2261","volume":"13","author":"DN Florescu","year":"2023","unstructured":"Florescu DN, Boldeanu MV, Serban RE, Florescu LM, Serbanescu MS, Ionescu M, et al. Correlation of the pro-inflammatory cytokines IL-1beta, IL-6, and TNF-alpha, inflammatory markers, and tumor markers with the diagnosis and prognosis of colorectal cancer. Life (Basel). 2023;13(12):2261.","journal-title":"Life (Basel)"},{"key":"4566_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155205","volume":"135","author":"S Najdaghi","year":"2020","unstructured":"Najdaghi S, Razi S, Rezaei N. An overview of the role of interleukin-8 in colorectal cancer. Cytokine. 2020;135:155205.","journal-title":"Cytokine"},{"issue":"6","key":"4566_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179065","volume":"12","author":"T Mohr","year":"2017","unstructured":"Mohr T, Haudek-Prinz V, Slany A, Grillari J, Micksche M, Gerner C. Proteome profiling in IL-1beta and VEGF-activated human umbilical vein endothelial cells delineates the interlink between inflammation and angiogenesis. PLoS ONE. 2017;12(6):e0179065.","journal-title":"PLoS ONE"},{"key":"4566_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.618839","volume":"11","author":"MA Nisar","year":"2021","unstructured":"Nisar MA, Zheng Q, Saleem MZ, Ahmmed B, Ramzan MN, Ud Din SR, et al. IL-1beta promotes vasculogenic mimicry of breast cancer cells through p38\/MAPK and PI3K\/Akt signaling pathways. Front Oncol. 2021;11:618839.","journal-title":"Front Oncol"},{"issue":"51","key":"4566_CR37","doi-asserted-by":"publisher","first-page":"29820","DOI":"10.18632\/oncotarget.25661","volume":"9","author":"N Vainer","year":"2018","unstructured":"Vainer N, Dehlendorff C, Johansen JS. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer. Oncotarget. 2018;9(51):29820\u201341.","journal-title":"Oncotarget"},{"issue":"2","key":"4566_CR38","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002502","volume":"95","author":"J Xu","year":"2016","unstructured":"Xu J, Ye Y, Zhang H, Szmitkowski M, M\u00e4kinen MJ, Li P, et al. Diagnostic and prognostic value of serum interleukin-6 in colorectal cancer. Medicine (Baltimore). 2016;95(2):e2502.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"4566_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123484","volume":"10","author":"W Xia","year":"2015","unstructured":"Xia W, Chen W, Zhang Z, Wu D, Wu P, Chen Z, et al. Prognostic value, clinicopathologic features and diagnostic accuracy of interleukin-8 in colorectal cancer: a meta-analysis. PLoS ONE. 2015;10(4):e0123484.","journal-title":"PLoS ONE"},{"key":"4566_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102631","author":"C Bazzichetto","year":"2022","unstructured":"Bazzichetto C, Milella M, Zampiva I, Simionato F, Amoreo CA, Buglioni S, et al. Interleukin-8 in colorectal cancer: a systematic review and meta-analysis of its potential role as a prognostic biomarker. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10102631.","journal-title":"Biomedicines"},{"issue":"4","key":"4566_CR41","doi-asserted-by":"publisher","first-page":"420","DOI":"10.5195\/jmla.2018.345","volume":"106","author":"MB Eriksen","year":"2018","unstructured":"Eriksen MB, Frandsen TF. The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review. J Med Libr Assoc. 2018;106(4):420\u201331.","journal-title":"J Med Libr Assoc"},{"key":"4566_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"9","key":"4566_CR43","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"issue":"7109","key":"4566_CR44","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"3","key":"4566_CR45","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","volume":"74","author":"L Lin","year":"2018","unstructured":"Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics. 2018;74(3):785\u201394.","journal-title":"Biometrics"},{"issue":"2","key":"4566_CR46","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10434-000-0133-7","volume":"7","author":"C Belluco","year":"2000","unstructured":"Belluco C, Nitti D, Frantz M, Toppan P, Basso D, Plebani M, et al. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol. 2000;7(2):133\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"16","key":"4566_CR47","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1002\/cncr.26726","volume":"118","author":"SL Chan","year":"2012","unstructured":"Chan SL, Mo FKF, Wong CSC, Chan CML, Leung LKS, Hui EP, et al. A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. Cancer. 2012;118(16):3984\u201392.","journal-title":"Cancer"},{"issue":"3","key":"4566_CR48","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/ijc.29017","volume":"136","author":"ZY Chen","year":"2015","unstructured":"Chen ZY, He WZ, Peng LX, Jia WH, Guo RP, Xia LP, et al. A prognostic classifier consisting of 17 circulating cytokines is a novel predictor of overall survival for metastatic colorectal cancer patients. Int J Cancer. 2015;136(3):584\u201392.","journal-title":"Int J Cancer"},{"issue":"3","key":"4566_CR49","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/bjc.2013.781","volume":"110","author":"ZY Chen","year":"2014","unstructured":"Chen ZY, Wei W, Guo ZX, Peng LX, Shi M, Li SH, et al. Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts. Br J Cancer. 2014;110(3):733\u201340.","journal-title":"Br J Cancer"},{"key":"4566_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-102","author":"HW Chung","year":"2014","unstructured":"Chung HW, Lim JB. Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma. J Transl Med. 2014. https:\/\/doi.org\/10.1186\/1479-5876-12-102.","journal-title":"J Transl Med"},{"issue":"12","key":"4566_CR51","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1002\/cncr.20672","volume":"101","author":"B Ebrahimi","year":"2004","unstructured":"Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinoma: Correlation with phenotypic characteristics and prognosis. Cancer. 2004;101(12):2727\u201336.","journal-title":"Cancer"},{"key":"4566_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7120502","author":"YC Hou","year":"2018","unstructured":"Hou YC, Wang CJ, Chao YJ, Chen HY, Wang HC, Tung HL, et al. Elevated serum interleukin-8 level correlates with cancer-related cachexia and sarcopenia: an indicator for pancreatic cancer outcomes. J Clin Med. 2018. https:\/\/doi.org\/10.3390\/jcm7120502.","journal-title":"J Clin Med"},{"issue":"2","key":"4566_CR53","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/jso.23247","volume":"107","author":"T Iwata","year":"2013","unstructured":"Iwata T, Tanaka K, Inoue Y, Toiyama Y, Hiro J, Fujikawa H, et al. Macrophage inflammatory protein-3 alpha (MIP-3a) is a novel serum prognostic marker in patients with colorectal cancer. J Surg Oncol. 2013;107(2):160\u20136.","journal-title":"J Surg Oncol"},{"issue":"3","key":"4566_CR54","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.cyto.2012.07.017","volume":"60","author":"JW Jang","year":"2012","unstructured":"Jang JW, Oh BS, Kwon JH, You CR, Chung KW, Kay CS, et al. Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine. 2012;60(3):686\u201393.","journal-title":"Cytokine"},{"issue":"14","key":"4566_CR55","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1016\/j.ejca.2011.11.032","volume":"48","author":"M Kawamura","year":"2012","unstructured":"Kawamura M, Toiyama Y, Tanaka K, Saigusa S, Okugawa Y, Hiro J, et al. CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. Eur J Cancer. 2012;48(14):2244\u201351.","journal-title":"Eur J Cancer"},{"issue":"2","key":"4566_CR56","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/1078-0432.CCR-07-1032","volume":"14","author":"WC Liao","year":"2008","unstructured":"Liao WC, Lin JT, Wu CY, Huang SP, Lin MT, Wu AS, et al. Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin Cancer Res. 2008;14(2):428\u201334.","journal-title":"Clin Cancer Res"},{"key":"4566_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19061766","author":"SH Loosen","year":"2018","unstructured":"Loosen SH, Schulze-Hagen M, Leyh C, Benz F, Vucur M, Kuhl C, et al. IL-6 and IL-8 serum levels predict tumor response and overall survival after TACE for primary and secondary hepatic malignancies. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19061766.","journal-title":"Int J Mol Sci"},{"issue":"SUPPL. 3","key":"4566_CR58","doi-asserted-by":"publisher","first-page":"S518","DOI":"10.1245\/s10434-011-1993-8","volume":"19","author":"K Matsushita","year":"2012","unstructured":"Matsushita K, Toiyama Y, Tanaka K, Saigusa S, Hiro J, Uchida K, et al. Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients. Ann Surg Oncol. 2012;19(SUPPL. 3):S518\u201327.","journal-title":"Ann Surg Oncol"},{"key":"4566_CR59","doi-asserted-by":"publisher","first-page":"v27","DOI":"10.1093\/annonc\/mdx363.017","volume":"28","author":"D Melisi","year":"2017","unstructured":"Melisi D, Piro G, Simionato F, Carbone C, Frizziero M, Malleo G, et al. A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. Ann Oncol. 2017;28:v27.","journal-title":"Ann Oncol"},{"issue":"17","key":"4566_CR60","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.1158\/1078-0432.CCR-20-0395","volume":"26","author":"V Merz","year":"2020","unstructured":"Merz V, Zecchetto C, Santoro R, Simionato F, Sabbadini F, Mangiameli D, et al. Plasma IL8 is a biomarker for TAK1 activation and predicts resistance to nanoliposomal irinotecan in patients with gemcitabine-refractory pancreatic cancer. Clin Cancer Res. 2020;26(17):4661\u20139.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"4566_CR61","first-page":"3504","volume":"7","author":"R Parasole","year":"2001","unstructured":"Parasole R, Izzo F, Perrone F, Pignata S, Galati MG, Leonardi E, et al. Prognostic value of serum biological markers in patients with hepatocellular carcinoma. Clin Cancer Res. 2001;7(11):3504\u20139.","journal-title":"Clin Cancer Res"},{"key":"4566_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236569","author":"R Peltonen","year":"2020","unstructured":"Peltonen R, Gramkow MH, Dehlendorff C, Osterlund PJ, Johansen JS, Isoniemi H. Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases. PLoS ONE. 2020. https:\/\/doi.org\/10.1371\/journal.pone.0236569.","journal-title":"PLoS ONE"},{"issue":"4","key":"4566_CR63","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/jso.24335","volume":"114","author":"Y Okugawa","year":"2016","unstructured":"Okugawa Y, Toiyama Y, Mohri Y, Tanaka K, Kawamura M, Hiro J, et al. Elevated serum concentration of monocyte chemotactic protein 4 (MCP-4) as a novel non-invasive prognostic and predictive biomarker for detection of metastasis in colorectal cancer. J Surg Oncol. 2016;114(4):483\u20139.","journal-title":"J Surg Oncol"},{"issue":"3","key":"4566_CR64","doi-asserted-by":"publisher","first-page":"107","DOI":"10.14715\/cmb\/2021.67.3.14","volume":"67","author":"L Petrusel","year":"2021","unstructured":"Petrusel L, Ilies M, Leucuta D, Rusu I, Seicean A, Iuga C, et al. Serum JAK\/STAT profile is related to the IL expression but not with the outcome in pancreatic adenocarcinoma patients. Cell Mol Biol. 2021;67(3):107\u201312.","journal-title":"Cell Mol Biol"},{"issue":"2","key":"4566_CR65","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.pan.2019.01.015","volume":"19","author":"L Qian","year":"2019","unstructured":"Qian L, Yu SL, Yin CQ, Zhu B, Chen Z, Meng ZQ, et al. Plasma IFN-gamma-inducible chemokines CXCL9 and CXCL10 correlate with survival and chemotherapeutic efficacy in advanced pancreatic ductal adenocarcinoma. Pancreatology. 2019;19(2):340\u20135.","journal-title":"Pancreatology"},{"key":"4566_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067059","author":"NA Schultz","year":"2013","unstructured":"Schultz NA, Christensen IJ, Werner J, Giese N, Jensen BV, Larsen O, et al. Diagnostic and prognostic impact of circulating YKL-40, IL-6, and CA 19.9 in patients with pancreatic cancer. PLoS ONE. 2013. https:\/\/doi.org\/10.1371\/journal.pone.0067059.","journal-title":"PLoS ONE"},{"issue":"17","key":"4566_CR67","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/cncr.29440","volume":"121","author":"MS Shah","year":"2015","unstructured":"Shah MS, Fogelman DR, Raghav KP, Heymach JV, Tran HT, Jiang ZQ, et al. Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. Cancer. 2015;121(17):2968\u201375.","journal-title":"Cancer"},{"issue":"10","key":"4566_CR68","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/jjco\/hyx103","volume":"47","author":"YY Shao","year":"2017","unstructured":"Shao YY, Lin H, Li YS, Lee YH, Chen HM, Cheng AL, et al. High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma. Jpn J Clin Oncol. 2017;47(10):949\u201353.","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"4566_CR69","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1515\/med-2021-0407","volume":"17","author":"G Herczeg","year":"2022","unstructured":"Herczeg G, Somogyi A, Herold M, Fodor A, Rosta K, Dank M, et al. Does diabetes affect paraneoplastic thrombocytosis in colorectal cancer? Open Med. 2022;17(1):160\u201373.","journal-title":"Open Med"},{"issue":"13","key":"4566_CR70","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.12998\/wjcc.v10.i13.4084","volume":"10","author":"Z Herold","year":"2022","unstructured":"Herold Z, Herold M, Herczeg G, Fodor A, Szasz AM, Dank M, et al. High plasma CD40 ligand level is associated with more advanced stages and worse prognosis in colorectal cancer. World J Clin Cases. 2022;10(13):4084\u201396.","journal-title":"World J Clin Cases"},{"issue":"9","key":"4566_CR71","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1007\/s00262-021-03137-6","volume":"71","author":"M Lanki","year":"2022","unstructured":"Lanki M, Sepp\u00e4nen H, Mustonen H, Salmiheimo A, Stenman UH, Salmi M, et al. Pancreatic cancer survival prediction via inflammatory serum markers. Cancer Immunol Immunother. 2022;71(9):2287\u201392.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"4566_CR72","first-page":"1341","volume":"26","author":"T Man","year":"2022","unstructured":"Man T, Seicean R, Lucaciu L, Leucuta D, Ilies M, Iuga C, et al. Leptin involvement in the survival of pancreatic adenocarcinoma patients with obesity and diabetes. Eur Rev Med Pharmacol Sci. 2022;26(4):1341\u20139.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"8","key":"4566_CR73","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1245\/s10434-018-6532-4","volume":"25","author":"PW Yang","year":"2018","unstructured":"Yang PW, Huang PM, Yong LS, Chang YH, Wu CW, Hua KT, et al. Circulating interleukin-6 is associated with prognosis and genetic polymorphisms of MIR608 in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2018;25(8):2449\u201356.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"4566_CR74","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/17246008211022769","volume":"36","author":"YL Yu","year":"2021","unstructured":"Yu YL, Fan CW, Tseng WK, Chang PH, Kuo HC, Pan YP, et al. Correlation between the Glasgow prognostic score and the serum cytokine profile in Taiwanese patients with colorectal cancer. Int J Biol Markers. 2021;36(2):40\u20139.","journal-title":"Int J Biol Markers"},{"issue":"46","key":"4566_CR75","doi-asserted-by":"publisher","first-page":"75013","DOI":"10.18632\/oncotarget.12601","volume":"7","author":"M Thomsen","year":"2016","unstructured":"Thomsen M, Kersten C, Sorbye H, Skovlund E, Glimelius B, Pfeiffer P, et al. Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. Oncotarget. 2016;7(46):75013\u201322.","journal-title":"Oncotarget"},{"key":"4566_CR76","doi-asserted-by":"publisher","first-page":"9701574","DOI":"10.1155\/2016\/9701574","volume":"2016","author":"K Shiga","year":"2016","unstructured":"Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Sato M, et al. Preoperative serum interleukin-6 is a potential prognostic factor for colorectal cancer, including stage II patients. Gastroenterol Res Pract. 2016;2016:9701574.","journal-title":"Gastroenterol Res Pract"},{"issue":"1","key":"4566_CR77","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/ijc.30040","volume":"139","author":"JP V\u00e4yrynen","year":"2016","unstructured":"V\u00e4yrynen JP, Kantola T, V\u00e4yrynen SA, Klintrup K, Bloigu R, Karhu T, et al. The relationships between serum cytokine levels and tumor infiltrating immune cells and their clinical significance in colorectal cancer. Int J Cancer. 2016;139(1):112\u201321.","journal-title":"Int J Cancer"},{"issue":"1","key":"4566_CR78","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00384-020-03748-y","volume":"36","author":"M Suenaga","year":"2021","unstructured":"Suenaga M, Mashima T, Kawata N, Wakatsuki T, Dan S, Seimiya H, et al. Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer. Int J Colorectal Dis. 2021;36(1):131\u20139.","journal-title":"Int J Colorectal Dis"},{"issue":"2","key":"4566_CR79","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/liv.13218","volume":"37","author":"SL Chan","year":"2017","unstructured":"Chan SL, Chan AW, Chan AK, Jian P, Mo F, Chan CM, et al. Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. Liver Int. 2017;37(2):280\u20139.","journal-title":"Liver Int"},{"issue":"21","key":"4566_CR80","doi-asserted-by":"publisher","first-page":"5655","DOI":"10.1158\/1078-0432.CCR-19-2700","volume":"26","author":"D H\u00f8gdall","year":"2020","unstructured":"H\u00f8gdall D, O\u2019Rourke CJ, Dehlendorff C, Larsen OF, Jensen LH, Johansen AZ, et al. Serum IL6 as a prognostic biomarker and IL6R as a therapeutic target in biliary tract cancers. Clin Cancer Res. 2020;26(21):5655\u201367.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4566_CR81","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pan.2018.11.002","volume":"19","author":"ML Ramsey","year":"2019","unstructured":"Ramsey ML, Talbert E, Ahn D, Bekaii-Saab T, Badi N, Bloomston PM, et al. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Pancreatology. 2019;19(1):80\u20137.","journal-title":"Pancreatology"},{"key":"4566_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041062","author":"TD Christensen","year":"2023","unstructured":"Christensen TD, Madsen K, Maag E, Larsen O, Jensen LH, Hansen CP, et al. Protein signatures and individual circulating proteins, including IL-6 and IL-15, associated with prognosis in patients with biliary tract cancer. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15041062.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"4566_CR83","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1097\/SLA.0000000000005997","volume":"278","author":"JD Karalis","year":"2023","unstructured":"Karalis JD, Ju MR, Yoon LY, Castro-Dubon EC, Reznik SI, Hammer STG, et al. Serum interleukin 6 level is associated with overall survival and treatment response in gastric and gastroesophageal junction cancer. Ann Surg. 2023;278(6):918\u201324.","journal-title":"Ann Surg"},{"key":"4566_CR84","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231211543","volume":"16","author":"P Liang","year":"2023","unstructured":"Liang P, Zhang Y, Jiang T, Jin T, Chen Z, Li Z, et al. Association between IL-6 and prognosis of gastric cancer: a retrospective study. Therap Adv Gastroenterol. 2023;16:17562848231211543.","journal-title":"Therap Adv Gastroenterol"},{"issue":"3","key":"4566_CR85","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10388-019-00708-6","volume":"17","author":"Y Maeda","year":"2020","unstructured":"Maeda Y, Takeuchi H, Matsuda S, Okamura A, Fukuda K, Miyasho T, et al. Clinical significance of preoperative serum concentrations of interleukin-6 as a prognostic marker in patients with esophageal cancer. Esophagus. 2020;17(3):279\u201388.","journal-title":"Esophagus"},{"key":"4566_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15071997","author":"PRA Pastrez","year":"2023","unstructured":"Pastrez PRA, Barbosa AM, Mariano VS, Causin RL, Castro AG, Torrado E, et al. Interleukin-8 and interleukin-6 are biomarkers of poor prognosis in esophageal squamous cell carcinoma. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15071997.","journal-title":"Cancers (Basel)"},{"key":"4566_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12040903","author":"SJ Park","year":"2024","unstructured":"Park SJ, Park JY, Shin K, Hong TH, Kim Y, Kim IH, et al. The role of pretreatment serum interleukin 6 in predicting short-term mortality in patients with advanced pancreatic cancer. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12040903.","journal-title":"Biomedicines"},{"key":"4566_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/cells12212532","author":"A Cavazzoni","year":"2023","unstructured":"Cavazzoni A, Digiacomo G. Role of cytokines and other soluble factors in tumor development: rationale for new therapeutic strategies. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12212532.","journal-title":"Cells"},{"issue":"1","key":"4566_CR89","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","volume":"9","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y, et al. Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduct Target Ther. 2024;9(1):132.","journal-title":"Signal Transduct Target Ther"},{"key":"4566_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.723846","volume":"9","author":"X Xiong","year":"2022","unstructured":"Xiong X, Liao X, Qiu S, Xu H, Zhang S, Wang S, et al. CXCL8 in tumor biology and its implications for clinical translation. Front Mol Biosci. 2022;9:723846.","journal-title":"Front Mol Biosci"},{"key":"4566_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107692","volume":"219","author":"K Fousek","year":"2021","unstructured":"Fousek K, Horn LA, Palena C. Interleukin-8: a chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression. Pharmacol Ther. 2021;219:107692.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"4566_CR92","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000326","volume":"8","author":"LA Horn","year":"2020","unstructured":"Horn LA, Riskin J, Hempel HA, Fousek K, Lind H, Hamilton DH, et al. Simultaneous inhibition of CXCR1\/2, TGF-beta, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity. J Immunother Cancer. 2020;8(1):e000326.","journal-title":"J Immunother Cancer"},{"key":"4566_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.731751","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang Z, Liu Y, Mo Y, Zhang H, Dai Z, Zhang X, et al. The CXCL family contributes to immunosuppressive microenvironment in gliomas and assists in gliomas chemotherapy. Front Immunol. 2021;12:731751.","journal-title":"Front Immunol"},{"issue":"1","key":"4566_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12920-023-01690-w","volume":"17","author":"X Liao","year":"2024","unstructured":"Liao X, Yang Y, Wang L, Kong Z, Li W. CC chemokine receptors are prognostic indicators of gastric cancer and are associated with immune infiltration. BMC Med Genomics. 2024;17(1):1.","journal-title":"BMC Med Genomics"},{"issue":"1","key":"4566_CR95","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13014-022-02038-x","volume":"17","author":"L Wang","year":"2022","unstructured":"Wang L, Jiang J, Chen Y, Jia Q, Chu Q. The roles of CC chemokines in response to radiation. Radiat Oncol. 2022;17(1):63.","journal-title":"Radiat Oncol"},{"issue":"1","key":"4566_CR96","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1038\/s41598-019-40514-9","volume":"9","author":"JK Thomas","year":"2019","unstructured":"Thomas JK, Mir H, Kapur N, Bae S, Singh S. CC chemokines are differentially expressed in breast cancer and are associated with disparity in overall survival. Sci Rep. 2019;9(1):4014.","journal-title":"Sci Rep"},{"issue":"9","key":"4566_CR97","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.7150\/ijbs.25349","volume":"14","author":"W Xu","year":"2018","unstructured":"Xu W, Wei Q, Han M, Zhou B, Wang H, Zhang J, et al. CCL2-SQSTM1 positive feedback loop suppresses autophagy to promote chemoresistance in gastric cancer. Int J Biol Sci. 2018;14(9):1054\u201366.","journal-title":"Int J Biol Sci"},{"issue":"6","key":"4566_CR98","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41416-020-0943-2","volume":"123","author":"A Hippe","year":"2020","unstructured":"Hippe A, Braun SA, Olah P, Gerber PA, Schorr A, Seeliger S, et al. EGFR\/Ras-induced CCL20 production modulates the tumour microenvironment. Br J Cancer. 2020;123(6):942\u201354.","journal-title":"Br J Cancer"},{"key":"4566_CR99","doi-asserted-by":"publisher","first-page":"9056173","DOI":"10.1155\/2018\/9056173","volume":"2018","author":"H Choudhry","year":"2018","unstructured":"Choudhry H, Helmi N, Abdulaal WH, Zeyadi M, Zamzami MA, Wu W, et al. Prospects of IL-2 in cancer immunotherapy. Biomed Res Int. 2018;2018:9056173.","journal-title":"Biomed Res Int"},{"issue":"6","key":"4566_CR100","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1163462","volume":"5","author":"T Jiang","year":"2016","unstructured":"Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016;5(6):e1163462.","journal-title":"Oncoimmunology"},{"key":"4566_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104539","volume":"90","author":"ME Raeber","year":"2023","unstructured":"Raeber ME, Sahin D, Karakus U, Boyman O. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases. EBioMedicine. 2023;90:104539.","journal-title":"EBioMedicine"},{"issue":"1","key":"4566_CR102","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01826-7","volume":"22","author":"S Muhammad","year":"2023","unstructured":"Muhammad S, Fan T, Hai Y, Gao Y, He J. Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies. Mol Cancer. 2023;22(1):121.","journal-title":"Mol Cancer"},{"key":"4566_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/srep11394","volume":"5","author":"G Tian","year":"2015","unstructured":"Tian G, Mi J, Wei X, Zhao D, Qiao L, Yang C, et al. Circulating interleukin-6 and cancer: a meta-analysis using Mendelian randomization. Sci Rep. 2015;5:11394.","journal-title":"Sci Rep"},{"issue":"7","key":"4566_CR104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181125","volume":"12","author":"EM Silva","year":"2017","unstructured":"Silva EM, Mariano VS, Pastrez PRA, Pinto MC, Castro AG, Syrjanen KJ, et al. High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer. PLoS ONE. 2017;12(7):e0181125.","journal-title":"PLoS ONE"},{"issue":"3","key":"4566_CR105","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1046\/j.1365-2567.2002.01501.x","volume":"107","author":"IH Heijink","year":"2002","unstructured":"Heijink IH, Vellenga E, Borger P, Postma DS, de Monchy JG, Kauffman HF. Interleukin-6 promotes the production of interleukin-4 and interleukin-5 by interleukin-2-dependent and -independent mechanisms in freshly isolated human T cells. Immunology. 2002;107(3):316\u201324.","journal-title":"Immunology"},{"issue":"11","key":"4566_CR106","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.tem.2023.08.001","volume":"34","author":"ST Orange","year":"2023","unstructured":"Orange ST, Leslie J, Ross M, Mann DA, Wackerhage H. The exercise IL-6 enigma in cancer. Trends Endocrinol Metab. 2023;34(11):749\u201363.","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"4566_CR107","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234\u201348.","journal-title":"Nat Rev Clin Oncol"},{"key":"4566_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063403","author":"K Felekkis","year":"2024","unstructured":"Felekkis K, Papaneophytou C. The circulating biomarkers league: combining miRNAs with cell-free DNAs and proteins. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25063403.","journal-title":"Int J Mol Sci"},{"key":"4566_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.plabm.2024.e00392","volume":"39","author":"F Romano","year":"2024","unstructured":"Romano F, Lanzilao L, Russo E, Infantino M, Nencini F, Cappelli G, et al. Comparison of ELISA with automated ECLIA for IL-6 determination in COVID-19 patients: an Italian real-life experience. Pract Lab Med. 2024;39:e00392.","journal-title":"Pract Lab Med"},{"issue":"2","key":"4566_CR110","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jri.2005.03.005","volume":"66","author":"NC dupont","year":"2005","unstructured":"dupont NC, Wang K, Wadhwa PD, Culhane JF, Nelson EL. Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. J Reprod Immunol. 2005;66(2):175\u201391.","journal-title":"J Reprod Immunol"},{"issue":"8","key":"4566_CR111","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/gerona\/63.8.879","volume":"63","author":"SX Leng","year":"2008","unstructured":"Leng SX, McElhaney JE, Walston JD, Xie D, Fedarko NS, Kuche GA. ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol A Biol Sci Med Sci. 2008;63(8):879\u201384.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"4566_CR112","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12885-021-07932-3","volume":"21","author":"MMA Chiamulera","year":"2021","unstructured":"Chiamulera MMA, Zancan CB, Remor AP, Cordeiro MF, Gleber-Netto FO, Baptistella AR. Salivary cytokines as biomarkers of oral cancer: a systematic review and meta-analysis. BMC Cancer. 2021;21(1):205.","journal-title":"BMC Cancer"},{"issue":"3","key":"4566_CR113","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2326-6066.CIR-13-0214","volume":"2","author":"M Oft","year":"2014","unstructured":"Oft M. IL-10: master switch from tumor-promoting inflammation to antitumor immunity. Cancer Immunol Res. 2014;2(3):194\u20139.","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"4566_CR114","doi-asserted-by":"publisher","first-page":"12759","DOI":"10.21037\/apm-21-3471","volume":"10","author":"Y Liu","year":"2021","unstructured":"Liu Y, Gao Y, Lin T. Expression of interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-alpha) in non-small cell lung cancer and its relationship with the occurrence and prognosis of cancer pain. Ann Palliat Med. 2021;10(12):12759\u201366.","journal-title":"Ann Palliat Med"},{"issue":"1","key":"4566_CR115","doi-asserted-by":"publisher","first-page":"Itad011","DOI":"10.1093\/immadv\/ltad011","volume":"3","author":"MJ Walsh","year":"2023","unstructured":"Walsh MJ, Ali LR, Lenehan P, Kureshi CT, Kureshi R, Dougan M, et al. Blockade of innate inflammatory cytokines TNFalpha, IL-1beta, or IL-6 overcomes virotherapy-induced cancer equilibrium to promote tumor regression. Immunother Adv. 2023;3(1):Itad011.","journal-title":"Immunother Adv"},{"issue":"11","key":"4566_CR116","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157788","volume":"7","author":"B Yuan","year":"2022","unstructured":"Yuan B, Clowers MJ, Velasco WV, Peng S, Peng Q, Shi Y, et al. Targeting IL-1beta as an immunopreventive and therapeutic modality for K-ras-mutant lung cancer. JCI Insight. 2022;7(11):e157788.","journal-title":"JCI Insight"},{"key":"4566_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101799","volume":"38","author":"K Mirjacic Martinovic","year":"2023","unstructured":"Mirjacic Martinovic K, Vuletic A, TismaMiletic N, BesuZizak I, Milovanovic J, Matkovic S, et al. Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients. Transl Oncol. 2023;38:101799.","journal-title":"Transl Oncol"},{"issue":"12","key":"4566_CR118","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1007\/s10620-016-4270-7","volume":"61","author":"X Qiu","year":"2016","unstructured":"Qiu X, Wang X, Song Y, Chen L. Plasma level of interleukin-35 as an independent prognostic indicator in hepatocellular carcinoma. Dig Dis Sci. 2016;61(12):3513\u201321.","journal-title":"Dig Dis Sci"},{"issue":"10","key":"4566_CR119","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/bjs.4594","volume":"91","author":"RT Poon","year":"2004","unstructured":"Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg. 2004;91(10):1354\u201360.","journal-title":"Br J Surg"},{"issue":"1","key":"4566_CR120","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1478-3231.2004.00882.x","volume":"24","author":"K Okumoto","year":"2004","unstructured":"Okumoto K, Hattori E, Tamura K, Kiso S, Watanabe H, Saito K, et al. Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int. 2004;24(1):21\u20138.","journal-title":"Liver Int"},{"issue":"9","key":"4566_CR121","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/hepr.13350","volume":"49","author":"Y Noda","year":"2019","unstructured":"Noda Y, Kawaguchi T, Korenaga M, Yoshio S, Komukai S, Nakano M, et al. High serum interleukin-34 level is a predictor of poor prognosis in patients with non-viral hepatocellular carcinoma. Hepatol Res. 2019;49(9):1046\u201353.","journal-title":"Hepatol Res"},{"key":"4566_CR122","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-286","volume":"11","author":"NN Rahbari","year":"2011","unstructured":"Rahbari NN, Schmidt T, Falk CS, Hinz U, Herber M, Bork U, et al. Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. BMC Cancer. 2011;11:286.","journal-title":"BMC Cancer"},{"issue":"1","key":"4566_CR123","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/ajco.13403","volume":"17","author":"JH Gu","year":"2021","unstructured":"Gu JH, Wang XG, Wang LQ, Zhou LN, Tang M, Li P, et al. Serum level of interleukin-35 as a potential prognostic factor for gastric cancer. Asia Pac J Clin Oncol. 2021;17(1):52\u20139.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"3","key":"4566_CR124","doi-asserted-by":"publisher","first-page":"223","DOI":"10.9738\/INTSURG-D-13-00259.1","volume":"99","author":"S Saigusa","year":"2014","unstructured":"Saigusa S, Tanaka K, Inoue Y, Toiyama Y, Okugawa Y, Iwata T, et al. Low serum interleukin-13 levels correlate with poorer prognoses for colorectal cancer patients. Int Surg. 2014;99(3):223\u20139.","journal-title":"Int Surg"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04566-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04566-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04566-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:02:24Z","timestamp":1791392544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04566-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":124,"alternative-id":["4566"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04566-4","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"26 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this systematic review was only based on published data already in the public domain, ethical approval is not required. The findings of this systematic review have been disseminated through an international peer-reviewed journal publication and several scientific conference presentations.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}